RxDoctor Payments Data

Jessica Francis, PA

Medical · Fremont, NENPI 1124042569

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.3% of the total across 166 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 36 manufacturers reported payments, led by AbbVie at 24.4% of the total. 2025 is the largest year on record at $782, 2.2 times the $362 reported in 2021.

$2,714in general payments, 2019–2025

Across 166 payments — averaging $16.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$662
  • Amgen$250
  • Otsuka America Pharmaceutical, Inc.$239
  • Novo Nordisk$238
  • Pfizer$164
  • Boehringer Ingelheim$142
  • plus $1K from 30 others

What the payments were for

  • Food & beverage$2,66898%
  • Other$452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,714 in reported general payments places this provider in the 80th percentile of 216 medical providers in Nebraska.

See all medical providers in Nebraska

Medicare billing

Part B allowed, 2024
$66,544
Medicare patients
180
Services billed
1,838

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide21$19,826
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$19,322
JardianceEmpagliflozin17$17,184
VraylarCariprazine Hcl11$16,541
EliquisApixaban11$11,049
Levothyroxine Sodium132$1,329
Atorvastatin Calcium164$1,253
Novolin 70-30Insulin Nph Hum/Reg Insulin Hm12$1,135
Valsartan59$1,035
Rosuvastatin Calcium86$917
Fluticasone Propionate60$898
Esomeprazole Magnesium14$722
Bupropion XlBupropion Hcl25$698
Metoprolol Succinate88$650
Losartan Potassium70$648

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$238$19,82621 claims
Boehringer IngelheimJardiance$142$17,18417 claims
AbbVieVraylar$662$16,54111 claims
PfizerEliquis$164$11,04911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 216 medical providers in Nebraska.

Other medical in Fremont

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →